Eledon Pharmaceuticals (NASDAQ:ELDN – Get Free Report) and TELA Bio (NASDAQ:TELA – Get Free Report) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, valuation, analyst recommendations, profitability, dividends, institutional ownership and risk.
Earnings & Valuation
This table compares Eledon Pharmaceuticals and TELA Bio”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Eledon Pharmaceuticals | N/A | N/A | -$36.18 million | ($1.17) | -2.32 |
| TELA Bio | $69.30 million | 0.85 | -$37.84 million | ($1.12) | -1.33 |
Insider and Institutional Ownership
56.8% of Eledon Pharmaceuticals shares are owned by institutional investors. Comparatively, 94.4% of TELA Bio shares are owned by institutional investors. 12.3% of Eledon Pharmaceuticals shares are owned by company insiders. Comparatively, 4.7% of TELA Bio shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Risk and Volatility
Eledon Pharmaceuticals has a beta of 0.4, meaning that its share price is 60% less volatile than the S&P 500. Comparatively, TELA Bio has a beta of 0.91, meaning that its share price is 9% less volatile than the S&P 500.
Analyst Ratings
This is a summary of current ratings for Eledon Pharmaceuticals and TELA Bio, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Eledon Pharmaceuticals | 1 | 1 | 3 | 0 | 2.40 |
| TELA Bio | 1 | 1 | 1 | 0 | 2.00 |
Eledon Pharmaceuticals presently has a consensus price target of $10.00, indicating a potential upside of 269.00%. TELA Bio has a consensus price target of $4.50, indicating a potential upside of 202.01%. Given Eledon Pharmaceuticals’ stronger consensus rating and higher probable upside, equities research analysts plainly believe Eledon Pharmaceuticals is more favorable than TELA Bio.
Profitability
This table compares Eledon Pharmaceuticals and TELA Bio’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Eledon Pharmaceuticals | N/A | -92.51% | -38.31% |
| TELA Bio | -54.12% | -329.48% | -57.34% |
Summary
Eledon Pharmaceuticals beats TELA Bio on 8 of the 13 factors compared between the two stocks.
About Eledon Pharmaceuticals
Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. The company uses its immunology expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS). The company's lead compound in development is tegoprubart, an IgG1 and anti-CD40L antibody with high affinity for CD40 Ligand, a biological target with therapeutic potential. It has a collaboration agreement with eGenesis, Inc. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.
About TELA Bio
TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs. It markets its products through a single direct sales force, principally in the United States. The company was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.
Receive News & Ratings for Eledon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eledon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
